Lynda Charters Enoch started her early “eye life” at the Schepens Eye Research Institute, Boston, which ultimately culminated in her current position as an Editor of Ophthalmology Times.
APAO 2023: Beveled tip probe added to arsenal for retinal detachment vitrectomy
February 24th 2023Yusuke Oshima, MD, PhD, in a presentation at the 38th Asia-Pacific Academy of Ophthalmology Congress, Kuala Lumpur, Malaysia, discussed the advantages of using a beveled-tip ultra-speed probe for complete vitreous shaving during retinal detachment vitrectomies.
Read More
APAO 2023: Step therapy from Bevacizumab to Aflibercept for DME
February 24th 2023Voraporn Chaikitmongkol, MD, discussed step therapy and reported the results of a major study, the Diabetic Retinopathy Clinical Research (DRCR) Protocol AC, at the 38th Asia-Pacific Academy of Ophthalmology Congress, in Kuala Lumpur, Malaysia.
Read More
APAO 2023: Looking at anatomic outcomes in matched comparison: TENAYA and LUCERNE data
February 23rd 2023Greater anatomic improvements (central subfield thickness reduction, proportion with absence of subretinal fluid and intraretinal fluid) were seen with faricimab versus aflibercept during the matched dosing period (week 4, week 8, and week 12).
Read More
FDA: Apellis' pegcetacoplan approved for the treatment of geographic atrophy
February 17th 2023Apellis has received FDA approval for intravitreal pegcetacoplan (SYFOVRE) to treat geographic atrophy secondary to AMD. This news follows the submission of the 24-month phase 3 data in November 2022.
Read More
Networking and social activities abound for APAO delegates
February 15th 2023The agenda includes the Opening Ceremony, Women in Ophthalmology Luncheon, and Young Ophthalmologists’ Night, and that's only a sampling. The results of the APAO-Asia-Pacific Ocular Imaging Competition will also be announced.
Read More
Angiogenesis 2023: The mystery of geographic atrophy shifts with data
February 10th 2023In a presentation at the 2023 Angiogenesis, Exudation, and Degeneration program, Usha Chakravarthy, PhD, FRCOphth, CBE, presented data from the trial of lampalizumab, which is peeling back some of the mystery shrouding geographic atrophy.
Read More
Angiogenesis 2023: Using ophthalmic artery angioplasty to treat AMD
February 10th 2023In a presentation at Bascom Palmer’s 2023 Angiogenesis, Exudation, and Degeneration conference in Miami, Pedro Lylyk, MD, said ophthalmic artery angioplasty could prove to be a treatment option for patients diagnosed with age-related macular degeneration.
Read More
Angiogenesis 2023: Comparing GA phenotypes and progression rates in Asians, non-Asians
February 10th 2023A study conducted by Gemmy Cheung, MBBS, FRCOphth and colleagues shows geographic atrophy (GA) lesion phenotypes, associated features, and growth rates differ between Asians and non-Asians.
Read More
In the study, investigators conducted a cross-sectional study with the goal of evaluating a correlation between the number of peer-reviewed publications published before a residency and the subsequent peer-reviewed publications or career choices of doctors who graduated from an ophthalmology residency program.
Read More
Investigators concluded that both formulations of AR-1105 were well-tolerated and provided clinically meaningful and sustained visual improvements in vision and decreased retinal thickening despite that some patients had difficult-to-treat BRVO or CRVO with longstanding edema.
Read More
Heavy silicone oil proves effective, safe for persistent full-thickness macular holes
December 31st 2022The use of heavy silicone oil tamponade in secondary surgery for persistent full-thickness macular holes is a safe and efficient surgical method. Best-corrected visual acuity and minimum linear diameter before surgery may be indicators for anatomical success.
Read More
Gene therapy offers improved retinal sensitivity, visual function, and mobility
December 11th 2022In a multicenter phase 1/2 safety study conducted in the US and UK, researchers conducted a dose-escalation trial of AAV5-RPGR that included low, intermediate, and high doses of the gene therapy administered to 3, 4, and 3 adults, respectively.
Read More